Kestra Medical Technologies, Ltd. (KMTS)
Nasdaq · Healthcare · Medical Instruments & Supplies
$28.34+3.32%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.7B
- 52-week range
- $17.34 – $30.00
- 52-week change
- +12.46%
- EPS (trailing)
- −$2.67
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Dec 14, 2026
Fiscal year to Apr 2026
- Revenue
- $95.1M (+59.03%)
- Net income
- −$132M
- Operating margin
- −141.6%
- Diluted EPS
- −$2.43
- Free cash flow
- −$117M
From the company’s annual report on SEC EDGAR.
About Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
Headquarters: Kirkland, United States · 443 employees · kestramedical.com